{{위키데이터 속성 추적}}
{{Infobox drug|Verifiedfields=verified|Watchedfields=verified|verifiedrevid=477237325|drug_name=아비라테론 아세테이트|image=Abiraterone acetate.svg|width=250|image2=Abiraterone-acetate-from-powder-xtal-Mercury-3D-balls-thin.png|USAN=abiraterone acetate|JAN=abiraterone acetate|BAN=abiraterone

<!-- Clinical data -->|tradename=Zytiga, Yonsa, others|Drugs.com={{drugs.com|monograph|abiraterone-acetate}}|MedlinePlus=a611046|licence_EU=yes|DailyMedID=Abiraterone_acetate|licence_US=abiraterone|pregnancy_AU=D|pregnancy_AU_comment=<ref name="Drugs.com pregnancy">{{웹 인용| title=Abiraterone Use During Pregnancy | website=Drugs.com | date=13 March 2020 | url=https://www.drugs.com/pregnancy/abiraterone.html | access-date=8 June 2020 | archive-date=25 November 2020 | archive-url=https://web.archive.org/web/20201125092244/https://www.drugs.com/pregnancy/abiraterone.html | url-status=live }}</ref>|routes_of_administration=[[경구 투여]]<ref name="Zytiga FDA label" /><ref name="Yonsa Label">{{웹 인용|title=Yonsa- abiraterone acetate tablet |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132 |website=[[DailyMed]] |date=5 June 2018 |access-date=15 November 2019 |archive-date=13 August 2020 |archive-url=https://web.archive.org/web/20200813152826/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132 |url-status=live }}</ref>|class=[[Antineoplastic]]|ATC_prefix=L02|ATC_suffix=BX03|legal_AU=S4|legal_AU_comment=<ref name=TGA />|legal_CA=Rx-only|legal_UK=POM|legal_UK_comment=<ref name=EMC />|legal_US=Rx-only|legal_US_comment=<ref name="Zytiga FDA label" /><ref name="Yonsa Label"/>|legal_EU=Rx-only|legal_EU_comment=<ref name="Zytiga FDA label" />|legal_status=Rx-only

<!-- Pharmacokinetic data -->|bioavailability=알려지지 않음 (공복 시 최대 50%일 수 있음)<ref name="pmid27106175">{{저널 인용| vauthors = Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP | title = Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide | journal = Clin Pharmacokinet | volume = 55 | issue = 11 | pages = 1369–1380 | date = November 2016 | pmid = 27106175 | pmc = 5069300 | doi = 10.1007/s40262-016-0403-6 }}</ref>|protein_bound=아비라테론: ~99.8% (알부민과 {{abbrlink|α<sub>1</sub>-AGp|alpha-1 acid glycoprotein}})<ref name="pmid27106175" /><ref name="Zytiga FDA label" /><ref name="Sternberg2014">{{웹 인용|url=http://meetinglibrary.asco.org/content/114000117-144|title=Meeting Library - Meeting Library|website=meetinglibrary.asco.org|access-date=9 September 2016|archive-date=20 September 2016|archive-url=https://web.archive.org/web/20160920120942/http://meetinglibrary.asco.org/content/114000117-144|url-status=live}}</ref>|metabolism=[[에스터레이스]], [[CYP3A4]], SULT2A1<ref name="Sternberg2014" />|metabolites=아비라테론 등<ref name="Zytiga FDA label" /><ref name="pmid27106175" />|elimination_half-life=아비라테론: 12–24시간<ref name="Zytiga FDA label" /><ref name="pmid27106175" /><ref name="Yonsa Label" />|excretion=대변: 88%<ref name="Zytiga FDA label" /><ref name="Sternberg2014" /><br />소변: 5%<ref name="Zytiga FDA label" /><ref name="Sternberg2014" /><ref name="Yonsa Label" />|CAS_number_Ref={{cascite|correct|CAS}}|CAS_number=154229-18-2|CAS_supplemental=<br />154229-19-3 (아비라테론)|PubChem=9821849|IUPHAR_ligand=9288|DrugBank_Ref={{drugbankcite|correct|drugbank}}|DrugBank=DBSALT001173|ChemSpiderID_Ref={{chemspidercite|correct|chemspider}}|ChemSpiderID=7997598|UNII_Ref={{fdacite|correct|FDA}}|UNII=EM5OCB9YJ6|KEGG=D09701|ChEBI=68639|ChEMBL_Ref={{ebicite|correct|EBI}}|ChEMBL=271227|synonyms=CB-7630; JNJ-212082; 17-(3-Pyridinyl)androsta-5,16-dien-3β-ol acetate

<!-- Chemical and physical data -->|IUPAC_name=[(3''S'',8''R'',9''S'',10''R'',13''S'',14''S'')-10,13-다이메틸-17-피리딘-3-일-2,3,4,7,8,9,11,12,14,15-데카하이드로-1''H''-사아클로펜타[''a'']페난트렌-3-일] 아세테이트|C=26|H=33|N=1|O=2|SMILES=CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C|StdInChI_Ref={{stdinchicite|correct|chemspider}}|StdInChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1|StdInChIKey_Ref={{stdinchicite|correct|chemspider}}|StdInChIKey=UVIQSJCZCSLXRZ-UBUQANBQSA-N|melting_point=144|melting_high=145|melting_notes=<ref>{{저널 인용| vauthors = Potter GA, Barrie SE, Jarman M, Rowlands MG | title = Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer | journal = Journal of Medicinal Chemistry | volume = 38 | issue = 13 | pages = 2463–2471 | date = June 1995 | pmid = 7608911 | doi = 10.1021/jm00013a022 | name-list-style = vanc }}</ref>}}'''아비라테론 아세테이트'''(Abiraterone acetate)는 '''자이티가'''(Zytiga)라는 이름으로 판매되고 있는 약제로, [[전립선암]] 치료제이다.<ref name="AHFS2019">{{웹 인용|url=https://www.drugs.com/monograph/abiraterone-acetate.html|title=Abiraterone Acetate Monograph for Professionals|website=Drugs.com|language=en|archive-url=https://web.archive.org/web/20120506190123/https://www.drugs.com/monograph/abiraterone-acetate.html|archive-date=6 May 2012|url-status=live|access-date=15 November 2019}}</ref> 특히 전이성 거세저항성 전립선암(mCRPC)과 전이성 거세민감성 전립선암(mCSPC)의 치료제인 [[코르티코스테로이드]]와 함께 쓰인다.<ref name="Zytiga FDA label">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|title=Zytiga- abiraterone acetate tablet, film coated|date=13 June 2019|website=[[DailyMed]]|archive-url=https://web.archive.org/web/20141113055410/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|archive-date=13 November 2014|url-status=live|access-date=15 November 2019}}</ref><ref name="Zytiga FDA label2">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|title=Zytiga- abiraterone acetate tablet, film coated|date=13 June 2019|website=[[DailyMed]]|archive-url=https://web.archive.org/web/20141113055410/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|archive-date=13 November 2014|url-status=live|access-date=15 November 2019}}</ref> 고환절제술 이후 혹은 생식샘자극호르몬분비호르몬 유사체와 함께 사용된다.<ref name="Zytiga FDA label3">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|title=Zytiga- abiraterone acetate tablet, film coated|date=13 June 2019|website=[[DailyMed]]|archive-url=https://web.archive.org/web/20141113055410/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|archive-date=13 November 2014|url-status=live|access-date=15 November 2019}}</ref> 경구 투여한다.<ref name="AHFS20196">{{웹 인용|url=https://www.drugs.com/monograph/abiraterone-acetate.html|title=Abiraterone Acetate Monograph for Professionals|website=Drugs.com|language=en|archive-url=https://web.archive.org/web/20120506190123/https://www.drugs.com/monograph/abiraterone-acetate.html|archive-date=6 May 2012|url-status=live|access-date=15 November 2019}}</ref>

일반적인 부작용으로는 졸음, 구토, 두통, 관절 통증, 고혈압, 종창, [[저칼륨혈증]], [[고혈당증|고혈당]], 열감, 설사, 기침 등이 있다.<ref name="AHFS20197">{{웹 인용|url=https://www.drugs.com/monograph/abiraterone-acetate.html|title=Abiraterone Acetate Monograph for Professionals|website=Drugs.com|language=en|archive-url=https://web.archive.org/web/20120506190123/https://www.drugs.com/monograph/abiraterone-acetate.html|archive-date=6 May 2012|url-status=live|access-date=15 November 2019}}</ref><ref name="Zytiga FDA label4">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|title=Zytiga- abiraterone acetate tablet, film coated|date=13 June 2019|website=[[DailyMed]]|archive-url=https://web.archive.org/web/20141113055410/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|archive-date=13 November 2014|url-status=live|access-date=15 November 2019}}</ref> 다른 심각한 부작용으로는 [[간부전]], 부신겉질부전 등이 있다.<ref name="Zytiga FDA label5">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|title=Zytiga- abiraterone acetate tablet, film coated|date=13 June 2019|website=[[DailyMed]]|archive-url=https://web.archive.org/web/20141113055410/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|archive-date=13 November 2014|url-status=live|access-date=15 November 2019}}</ref> 임신을 준비하는 남성은 피임을 권한다.<ref name="Zytiga FDA label5" /> 아비라테론 아세테이트로 투여되어 체네에서 아비라테론으로 전환된다.<ref name="Zytiga FDA label6">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|title=Zytiga- abiraterone acetate tablet, film coated|date=13 June 2019|website=[[DailyMed]]|archive-url=https://web.archive.org/web/20141113055410/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|archive-date=13 November 2014|url-status=live|access-date=15 November 2019}}</ref> 남성 호르몬 [[안드로겐]]의 생성을 차단하며 작용하는데 특히 CYP17A1 효소를 차단한다. 그렇게 함으로써 [[테스토스테론]]의 생성이 감소한다. 결과적으로 [[전립선암]]의 호르몬 작용을 막는다.<ref name="AHFS20199">{{웹 인용|url=https://www.drugs.com/monograph/abiraterone-acetate.html|title=Abiraterone Acetate Monograph for Professionals|website=Drugs.com|language=en|archive-url=https://web.archive.org/web/20120506190123/https://www.drugs.com/monograph/abiraterone-acetate.html|archive-date=6 May 2012|url-status=live|access-date=15 November 2019}}</ref>

아비라테론 아세테이트는 1995년에 발명 되었고 2011년에 미국과 유럽 연합에서 의료용으로 승인되었다.<ref name="Scowcroft2011">{{저널 인용|title=Where did abiraterone come from?|journal=Journal of Medicinal Chemistry|url=http://scienceblog.cancerresearchuk.org/2011/09/21/where-did-abiraterone-come-from/|date=21 September 2011|volume=38|issue=13|publisher=Cancer Research UK|pages=2463–2471|archive-url=https://web.archive.org/web/20110925093704/http://scienceblog.cancerresearchuk.org/2011/09/21/where-did-abiraterone-come-from/|archive-date=25 September 2011|url-status=live|access-date=28 September 2011|vauthors=Scowcroft H}}</ref><ref name="Zytiga FDA label7">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|title=Zytiga- abiraterone acetate tablet, film coated|date=13 June 2019|website=[[DailyMed]]|archive-url=https://web.archive.org/web/20141113055410/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|archive-date=13 November 2014|url-status=live|access-date=15 November 2019}}</ref> [[WHO 필수 의약품 목록]]에 있다.<ref name="WHO21st">{{서적 인용|title=World Health Organization model list of essential medicines: 21st list 2019|author-link=World Health Organization|year=2019|publisher=World Health Organization|location=Geneva|id=WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO|vauthors=((World Health Organization))|hdl=10665/325771|hdl-access=free}}</ref><ref name="WHO22nd">{{서적 인용|title=World Health Organization model list of essential medicines: 22nd list (2021)|author-link=World Health Organization|year=2021|publisher=World Health Organization|location=Geneva|id=WHO/MHP/HPS/EML/2021.02|vauthors=((World Health Organization))|hdl=10665/345533|hdl-access=free}}</ref> 이 약은 일반 약품으로 구매 가능하다.<ref>{{웹 인용|url=https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals|title=First Generic Drug Approvals|date=17 October 2022|website=U.S. Food and Drug Administration|access-date=28 November 2022}}</ref>

== 의학적 용도 ==
아비라테론 아세테이트는 프리드니손, [[코르티코스테로이드]]와 함께 사용 되어 전이성 거세저항성 전립선암(mCRPC)을 치료한다. 과거에는 전이성 거세저항성 전립선암(mCRPC)을 호르몬 저항, 혹은 호르몬 불응성 전립선 암 이라고 불렀다.<ref name="Zytiga FDA label8">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|title=Zytiga- abiraterone acetate tablet, film coated|date=13 June 2019|website=[[DailyMed]]|archive-url=https://web.archive.org/web/20141113055410/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|archive-date=13 November 2014|url-status=live|access-date=15 November 2019}}</ref><ref name="Zytiga EPAR">{{웹 인용|url=https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga|title=Zytiga EPAR|date=13 March 2019|work=[[European Medicines Agency]] (EMA)|archive-url=https://web.archive.org/web/20201227061227/https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga|archive-date=27 December 2020|url-status=live|access-date=15 November 2019}}</ref><ref name="EMC">{{웹 인용|url=https://www.medicines.org.uk/emc/product/2381/smpc|title=Zytiga 500 mg film-coated tablets - Summary of Product Characteristics (SmPC)|date=4 March 2019|work=electronic medicines compendium (emc)|publisher=Datapharm|archive-url=https://web.archive.org/web/20191115191031/https://www.medicines.org.uk/emc/product/2381/smpc|archive-date=15 November 2019|url-status=live|access-date=15 November 2019}}</ref><ref name="TGA">{{웹 인용|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-01395-3|title=Zytiga abiraterone acetate product information|date=1 March 2012|work=TGA eBusiness Services|publisher=Janssen-Cilag Pty Ltd|format=PDF|archive-url=https://web.archive.org/web/20201124100354/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-01395-3|archive-date=24 November 2020|url-status=live|access-date=24 January 2014}}</ref> 이는 가장 중요한 [[안드로겐]] 차단용법이나 안드로겐수용체 길항제를 통한 치료에 반응하지 않는 전립선암의 한 형태였다. 아비라테론 아세테이트는 이러한 기능으로 2011년 4월 28일에 미국 식품의약국(FDA)의 승인을 받았고, 그 뒤로도 2011년 9월 23일에 유럽 의약품 감독국(EMA), 2011년 9월 5일에 영국 의약품규제청(MHRA), 그리고 2012년 3월 1일에 호주식약처(TGA)의 승인을 받았다.<ref name="Zytiga EPAR2">{{웹 인용|url=https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga|title=Zytiga EPAR|date=13 March 2019|work=[[European Medicines Agency]] (EMA)|archive-url=https://web.archive.org/web/20201227061227/https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga|archive-date=27 December 2020|url-status=live|access-date=15 November 2019}}</ref><ref name="EMC2">{{웹 인용|url=https://www.medicines.org.uk/emc/product/2381/smpc|title=Zytiga 500 mg film-coated tablets - Summary of Product Characteristics (SmPC)|date=4 March 2019|work=electronic medicines compendium (emc)|publisher=Datapharm|archive-url=https://web.archive.org/web/20191115191031/https://www.medicines.org.uk/emc/product/2381/smpc|archive-date=15 November 2019|url-status=live|access-date=15 November 2019}}</ref><ref name="TGA2">{{웹 인용|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-01395-3|title=Zytiga abiraterone acetate product information|date=1 March 2012|work=TGA eBusiness Services|publisher=Janssen-Cilag Pty Ltd|format=PDF|archive-url=https://web.archive.org/web/20201124100354/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-01395-3|archive-date=24 November 2020|url-status=live|access-date=24 January 2014}}</ref> 호주에서는 거세저항성 전립선암을 프레드니손이나 프레드니솔론으로 치료할 때에는 호주의 의약품 관리 체계인 PBS(Pharmaceutical Benefits Scheme)의 지원을 받는다. 지원 조건은 환자가 최근에 항암 치료를 받고 있고 도시탁셀에 저항하거나 과민한 상태이며, WHO 기준 활동도가 2점 이하이며, 아비라테론 아세테이트에 대한 PBS의 보조금을 받아 치료를 받기 시작한 이후 질병의 진행이 없는 상태여야 한다.<ref>{{웹 인용|url=http://www.pbs.gov.au/medicine/item/2698B|title=Pharmaceutical Benefits Scheme - Abiraterone|work=Pharmaceutical Benefits Scheme|archive-url=https://web.archive.org/web/20201202160545/https://www.pbs.gov.au/medicine/item/2698B|archive-date=2 December 2020|url-status=live|access-date=24 January 2014}}</ref> Yonsa Mpred라는 제품명으로 판매되고 있는 아비라테론 아세테이트와 메틸프레드니솔론은 아비라테론 아세테이트(Yonsa)와 메틸프레드니솔론을 모두 포함하고 있는 합성물 패키지이다. 이 약품은 2022년 3월에 호주에서 의학 용도로 승인을 받았다.<ref name="Yonsa Mpred PI">{{웹 인용|url=http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2022-PI-01402-1|title=TGA eBS - Product and Consumer Medicine Information Licence}}</ref><ref name="Yonsa Mpred Summary">[https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=346890&agid=%28PrintDetailsPublic%29&actionid=1 YONSA MPRED abiraterone acetate 125 mg tablet bottle and methylprednisolone 4 mg tablet bottle composite pack]</ref><ref>[https://www.tga.gov.au/resources/artg/346890 YONSA MPRED (Sun Pharma ANZ Pty Ltd)]</ref>

== 금기증 ==
아비라테론 아세테이트에 [[과민증]]이 있는 사람이 복용해서는 안된다. 임산부 혹은 임신 가능성이 있는 여성은 복용할 수 없다고 설명되어 있으나,<ref name="Zytiga EPAR3">{{웹 인용|url=https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga|title=Zytiga EPAR|date=13 March 2019|work=[[European Medicines Agency]] (EMA)|archive-url=https://web.archive.org/web/20201227061227/https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga|archive-date=27 December 2020|url-status=live|access-date=15 November 2019}}</ref><ref name="PI">{{웹 인용|url=http://www.zytigahcp.com/pdf/full_prescribing_info.pdf|title=Zytiga prescribing information|date=May 2012|publisher=Janssen Biotech|archive-url=https://web.archive.org/web/20141113044418/http://www.zytigahcp.com/pdf/full_prescribing_info.pdf|archive-date=13 November 2014|url-status=dead|access-date=4 March 2016}}</ref> 여성은 이 약을 복용할 의학적인 이유가 전혀 없다. 임산부는 장갑을 착용하지 않고 이 약을 만지는 것조차 금기 한다..<ref name="PI" /> 기타 주의사항으로는 심각한 간장애 기저 질환, 알도스테론증, [[심부전]]과 [[고혈압]] 등 심혈관계 질환, [[저칼륨혈증]], [[부신기능부전|부신 기능부전]] 등이 있다.<ref name="MSR">{{웹 인용|url=http://reference.medscape.com/drug/zytiga-abiraterone-999651|title=Zytiga (abiraterone) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|archive-url=https://web.archive.org/web/20140202175321/http://reference.medscape.com/drug/zytiga-abiraterone-999651|archive-date=2 February 2014|url-status=live|access-date=24 January 2014}}</ref>

== 부작용 ==
'''빈도별 부작용'''

'''매우 흔함 (>10% 빈도):'''
{{div col|colwidth=18em}}
* [[요로 감염]]
* [[저칼륨혈증]]
* [[고혈압]]
* [[설사]]
* [[말초부종]]
{{div col end}}

'''흔함 (1-10% 빈도):'''

{{div col|colwidth=18em}}
* [[과중성지방혈증]]
* [[패혈증]]
* [[심부전]]
* [[협심증]]
* [[부정맥]]
* [[심박세동]]
* [[빈맥]]
* [[소화불량]]
* [[발진]]
* [[알라닌 아미노 전이 효소]] 증가
* [[아스파르테이트 아미노 전이 효소]] 증가
* 골절
* [[혈뇨]]
{{div col end}}

'''흔치 않음 (0.1-1% 빈도):'''

* 부신기능저하증
* 근질환
* [[횡문근융해증]]

'''희귀 (<0.1빈도):'''
* 알레르기성 폐포염

== 과다 복용 ==
아비라테론 아세테이트 과다 복용의 경험은 제한적이다.<ref name="Zytiga FDA label9">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|title=Zytiga- abiraterone acetate tablet, film coated|date=13 June 2019|website=[[DailyMed]]|archive-url=https://web.archive.org/web/20141113055410/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513|archive-date=13 November 2014|url-status=live|access-date=15 November 2019}}</ref> 아비라테론 아세테이트 과다복용에는 특별한 해독제가 없다. 과다 복용 치료는 심장과 간의 기능을 관찰하는 일반적인 보조 치료를 포함해야 한다. .<ref name="Zytiga FDA label9" />

== 상호작용 ==
아비라테론 아세테이트는 [[CYP3A4]] 기질이므로 CYP3A4를 강하게 억제하는 약물이나 유도물질과 동시에 투여 하면 안된다. CYP3A4 억제제로는 [[케토코나졸]], [[이트라코나졸]], [[클래리스로마이신]], [[아타자나비르]], 니프리핀, [[사퀴나비르]], [https://ko.dict.naver.com/#/entry/koko/1be6e0738782485da19fe06ca410e7b8 테리스로마이신], [[리토나비르]], [[인디나비르]], [https://terms.naver.com/entry.naver?docId=6036643&cid=59913&categoryId=59913 넬피나비어], [https://terms.naver.com/entry.naver?docId=6225684&cid=59913&categoryId=59913 보리코나졸] 등이 있고, 유도물질로는 [[페니토인]], [[카르바마제핀]], [[리팜피신]], [[리파부틴]], 리파펜틴, [[페노바르비탈]] 등이 있다.<ref name="MSR2">{{웹 인용|url=http://reference.medscape.com/drug/zytiga-abiraterone-999651|title=Zytiga (abiraterone) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|archive-url=https://web.archive.org/web/20140202175321/http://reference.medscape.com/drug/zytiga-abiraterone-999651|archive-date=2 February 2014|url-status=live|access-date=24 January 2014}}</ref><ref name="PI2">{{웹 인용|url=http://www.zytigahcp.com/pdf/full_prescribing_info.pdf|title=Zytiga prescribing information|date=May 2012|publisher=Janssen Biotech|archive-url=https://web.archive.org/web/20141113044418/http://www.zytigahcp.com/pdf/full_prescribing_info.pdf|archive-date=13 November 2014|url-status=dead|access-date=4 March 2016}}</ref> 이것들은 또한 CYP1A2, CYP2C9, CYP3A4를 억제하므로 마찬가지로 치료 범위가 작은 어떤 효소 물질과도 함께 투여 하면 안된다.<ref name="MSR3">{{웹 인용|url=http://reference.medscape.com/drug/zytiga-abiraterone-999651|title=Zytiga (abiraterone) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|archive-url=https://web.archive.org/web/20140202175321/http://reference.medscape.com/drug/zytiga-abiraterone-999651|archive-date=2 February 2014|url-status=live|access-date=24 January 2014}}</ref><ref name="PI3">{{웹 인용|url=http://www.zytigahcp.com/pdf/full_prescribing_info.pdf|title=Zytiga prescribing information|date=May 2012|publisher=Janssen Biotech|archive-url=https://web.archive.org/web/20141113044418/http://www.zytigahcp.com/pdf/full_prescribing_info.pdf|archive-date=13 November 2014|url-status=dead|access-date=4 March 2016}}</ref>
[[스피로놀락톤]]은 본래 항안드로겐 작용을 가지고 있으나, 안드로겐이 감소된 상황에서는 전립선암의 활성을 유도하며 안드로겐 수용체 작용제의 역할을 한다는 실험 결과도 있다..<ref>{{저널 인용|title=Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture|journal=Journal of Steroid Biochemistry|date=November 1988|volume=31|issue=5|pages=845–52|doi=10.1016/0022-4731(88)90295-6|pmid=2462135|vauthors=Luthy IA, Begin DJ, Labrie F}}</ref> 이러한 주장은 몇 가지 사례에 대한 연구 결과에 서술 되어 있다.<ref>{{저널 인용|title=Abiraterone and spironolactone in prostate cancer: a combination to avoid|journal=Acta Clinica Belgica|year=2019|volume=74|issue=6|pages=439–444|doi=10.1080/17843286.2018.1543827|pmid=30477405|vauthors=Dhondt B, Buelens S, Van Besien J, Beysens M, De Bleser E, Ost P, Lumen N|s2cid=53738534}}</ref>

== 약리학 ==

=== 약리학 ===

==== 항안드로겐 작용 ====


<references />

[[분류:5α-환원 효소 억제제]]
[[분류:아세트산 에스터]]
[[분류:안드로스탄]]
[[분류:항에스트로겐]]
[[분류:항당질 코르티코이드]]
[[분류:공액 다이엔]]
[[분류:CYP2D6 억제제]]
[[분류:CYP17A1 억제제]]
[[분류:호르몬성 항암제]]
[[분류:존슨앤드존슨의 제품]]
[[분류:전구약물]]
[[분류:스테로이드 설포트랜스퍼레이스 저해제]]
[[분류:스테로이드성 항안드로겐]]
[[분류:합성 에스트로겐]]
[[분류:세계 보건 기구 필수 의약품]]
[[분류:3-피리딜 화합물]]